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Abstract: Cancer is the leading cause of death in the world. Development of minimally 
invasive  biomarkers  for  early  detection  of  cancer  is  urgently  needed  to  reduce  high 
morbidity  and  mortality  associated  with  malignancy.  MicroRNAs  (miRNAs)  are  small 
regulatory RNAs that modulate the activity of specific mRNA targets and play important 
roles in a wide range of physiologic and pathologic processes. Recently, miRNAs were 
found to be dysregulated in a variety of diseases including cancer. Emerging evidence 
suggests  that  miRNAs  are  involved  in  tumor  initiation  and  progression.  Together,  the 
different expression profiles of miRNAs in cancer, and the stability of circulating miRNAs, 
make  them  new  potentially  clinical  biomarkers  for  cancer  diagnosis,  classification, 
therapeutic decisions, and prognosis. 
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1. Introduction 
Cancers are often diagnosed at a late stage with concomitant poor prognosis. The development of 
minimally invasive tests for the detection and monitoring of common epithelial malignancies could 
greatly reduce the worldwide health burden of cancer [1]. As the blood is easily accessible and taking a 
sample is lowly invasive, testable biomarkers found in blood would be especially useful. Conventional 
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strategies for blood-based biomarker discovery (e.g., circulating proteins, DNA, mRNA) have shown 
promise, but their clinical use has been limited due to lack of sufficient sensitivity, specificity, and 
stability  [1].  New  approaches  that  can  complement  and  improve  on  current  strategies  for  cancer 
detection are urgently needed. 
MiRNAs are small (typically 22 nt in size) regulatory RNA molecules that modulate the activity 
of specific mRNA targets and play important roles in a wide range of physiologic and pathologic 
processes [2]. Altered miRNA expression has been reported in various cancers, and the expression 
patterns of miRNAs in human cancer appear to be tissue-specific [3]. MiRNAs have shown great 
potential  as  tissue-based  markers  for  cancer  definition.  Recently,  the  findings  that  human  blood 
contains stably expressed miRNAs have revealed a great potential of circulating miRNA signature as 
disease  fingerprints  to  predict  survival  [4].  Due  to  their  size,  abundance,  tissue  specificity,  and 
relative stability in circulation, miRNAs hold promise as unique accessible biomarkers to detect and 
monitor cancer. 
2. MiRNA Function 
MiRNAs are small (22 nt), endogenous, single-stranded, non-coding regulatory RNA molecules. 
MiRNAs  genes  often  cluster  in  the  genome  and  are  transcribed  by  RNA  polymerase  II  to  form  
pri-miRNAs in the nucleus. Pri-miRNAs then undergo processing by two cellular nucleases, Drosha 
and Dicer, to generate mature miRNAs. In animals, miRNAs mostly bind to complementary sequences 
in the 3' untranslated region (UTR) of their target mRNAs and negatively regulate gene expression 
either by translational repression or degradation of the mRNA transcript. MiRBase (Release 14.0), the 
central database for miRNAs, lists 15,172 entries with 1048 human miRNAs until now [5]. Many 
miRNAs are well conserved across all species, suggesting a crucial role. Studies have shown that 
miRNAs  are  involved  in  various  biologic  processes  and  pathways  such  as
  cell  proliferation, 
differentiation, apoptosis, metabolism, and tissue morphogenesis. Recent data suggest a direct link 
between miRNAs and disease, and miRNA expression signatures are associated with various types of 
cancer. In addition, the discovery that miRNAs are often expressed in a very tissue-specific manner 
during development is also suggestive of a crucial role of miRNAs in specifying and maintaining 
tissue identity. 
3. Specific Expression of MiRNAs in Cancer 
It is now recognized that miRNAs are frequently dysregulated in various cancers [6]. A number of 
miRNAs were shown to be located in fragile regions of the human genome that are associated with 
cancer  [7].  Functional  studies  indicate  that  miRNAs  have  both  tumor  suppressive  and  oncogenic 
potential in human cancer [8]. Under-expressed miRNAs such as let-7 in lung cancer and miR-15/16 in 
leukemia are tumor suppressor genes, suppressing Ras and BCL2, respectively [9,10]. Over-expressed 
miRNAs, such as mir-21 and the cluster mir-17–92, are oncogenes, targeting tumor suppressors PTEN 
and  E2F1  in  solid  and  hematologic  malignancies,  respectively  [11].  Furthermore,  dysregulated 
miRNAs have been shown to play a crucial role in tumor initiation, progression, and metastasis, and 
are often associated with diagnosis, prognosis, and response to therapy [12–14]. With the development 
of technologies to detect the expression levels of hundreds of miRNAs at a time and the clear role of Int. J. Mol. Sci. 2011, 12                       
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miRNAs in cancers, groups began looking at miRNA profiles of different cancers. Lu [15] developed a 
method for bead-based miRNA profiling. Employing this technique on twenty different cancers, they 
found that each cancer had a specific miRNA profile and that most poorly differentiated tumors could 
be classified to their tissues of origin based on their miRNA expression levels. Furthermore, miRNA 
expression differentiates histology and predicts survival and relapse of lung cancer [9,16,17]. 
4. Circulating MiRNAs: Stable RNA Molecules 
Circulating miRNAs are not only abundant in blood, but also very stable, which are important 
prerequisites  as  clinical  biomarkers.  MiRNAs  are  well  resistant  to  plasma  RNases.  Mitchell  [18] 
compared the stability of endogenous miRNAs with synthetic miRNAs without homologous sequences 
into human plasma. The levels of endogenous miRNAs were not significantly altered, while synthetic 
miRNAs rapidly degraded when added directly to plasma. Chen [19] treated miRNAs with RNase A 
digestion, while 18s rRNA, 28s rRNA, GAPDH, β-actin, and U6 were used as controls. Surprisingly, 
more than half of the miRNAs remained intact after 3 h of exposure to RNase A. In contrast, all 
controls were rapidly degraded by RNase A. Furthermore, miRNAs remain stable after being subjected 
to harsh conditions including boiling, low/high pH, extended storage, freeze-thaw cycles and so on. 
MiRNAs  also  have  unusually  high  stability  in  formalin-fixed  tissues  [20].  The  mechanism  of 
resistance of miRNAs to RNase requires further studies. Of note, measurements obtained from plasma 
or serum were strongly correlated, indicating that both serum and plasma samples will be suitable for 
investigations of miRNAs as blood-based biomarkers [18]. 
In sum, miRNAs in the circulation are relatively stable, very accessible, low invasive, and easily 
testable biomarkers. 
5. The Origin and Function of Circulating MiRNAs in Tumors 
Circulating miRNAs in the blood of cancer patients could play the same important roles as miRNAs 
in tissues. However, the secretory mechanism and biological function of extracellular miRNAs remain 
unclear. Mitchell [18] used a mouse xenograft model where a human prostate cancer cell line was 
implanted into mice to show that there were tumor-derived miRNAs circulating in blood. The plasma 
miR-184 levels were 10-fold reduced after the surgical removal of tumor, which further suggested that 
miRNAs originated from the primary tumor [21]. Furthermore, employing Solexa deep sequencing, 
Chen identified specific expression patterns of serum miRNAs for lung cancer and colorectal cancer, 
providing evidence that both of these two cancers had specific serum-miRNA profiles. These reports 
clearly show that cancers affect miRNA levels in the circulation, although it is still unclear how tumor 
miRNAs come into the circulation.  
Tumor miRNAs may be present as a result of tumor cells dying and getting lysed or tumor cells 
releasing exosomes that contain miRNAs. Tumor-derived exosomes are small membrane vesicles of 
endocytic origin released by the tumor, which may play important roles in cell-cell communication [22]. 
Ceramide,  whose  biosynthesis  is  regulated  by  neutral  sphingomyelinase  2  (nSMase2),  triggers 
secretion  of  small  membrane  vesicles  called  exosomes  [23].  Furthermore,  Rabinowits  [24] 
demonstrated  that  there  was  a  close  correlation  between  circulating  miRNAs  of  tumor-derived Int. J. Mol. Sci. 2011, 12                       
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exosomes and tumor miRNAs in lung adenocarcinoma. Thus, exosomes could be an important source 
of miRNA in the circulation. 
6. Circulating MiRNAs: the Biomarkers of Tumors 
Through various techniques, numerous groups have shown that different cancer types have distinct 
miRNA  profiles,  summarized  in  Table  1.  These  findings  suggest  that  circulating  miRNAs  have 
potential use as novel biomarkers for diagnosis and prognosis, and may prove useful information in 
clinical management during the peri-operative period. 
Mitchell et al. [18] investigated that miRNAs originating from human prostate cancer xenografts 
enter into the circulation, are readily measured in plasma, and can robustly distinguish xenografted 
mice from controls. Their concepts extended to cancer in humans, where circulating levels of miR-141 
(a miRNA expressed in prostate cancer) can distinguish patients with prostate cancer from healthy 
controls. Furthermore, the elevated serum levels of miR-200a and miR-200b in most patients with 
pancreatic  cancer  could  have  diagnostic  utility  [25].  The  plasma  concentrations  of  miRNAs  
(miR-17-5p, miR-21, miR-106a, miR-106b) in gastric cancer [2,26], and miR-184 in squamous cell 
carcinoma patients [18], and miR-195 and let-7a in breast cancer [27], were significantly higher than 
controls, and significantly reduced further after the surgical removal of tumor. Otherwise, the relative 
amount  of  miR-92a  in  the  plasma  from  hepatocellular  carcinoma  (HCC)  patients  was  decreased 
compared with that from healthy donors, but was elevated after surgical treatment [28] .The reduction 
or  elevation  of  plasma  miRNA  levels  after  the  surgical  removal  of  tumor  further  confirmed  the 
correlation between miRNA and the primary tumors. Furthermore, Heneghan [27] found that specific 
circulating miRNAs correlated with certain pathological variables, namely nodal status and estrogen 
receptor status. 
Calin et al. [29] were the first to show that their miRNA microarray could differentiate between B 
cell chronic lymphocyte leukemia (CLL) cells and normal cells. Furthermore, they classified CLL 
samples into two different groups based on their miRNA profiles, and these profiles corresponded to 
high or low levels of a protein that is associated with a positive prognosis at low levels. The patients 
with diffuse large B cell lymphoma (DLBCL) had high serum levels of miR-21, which was associated 
with  improved  relapse-free  survival  [30].  This  result  is  consistent  with  their  previous  findings  in 
biopsy material from a different cohort of DLBCL patients, where high tumor miR-21 expression was 
also associated with a more favorable clinical outcome. Most recently, Leidinger [31] screened and 
filtered 51 differentially regulated miRNAs in blood cells of melanoma patients. With a subset of 
16 significantly deregulated miRNAs, the classification accuracy, specificity, and sensitivity reached 
97.4%, 95%, and 98.9% by supervised analysis. Hu [32] also found that the miRNA signature from the 
serum may predict overall survival of non-small cell lung cancer (NSCLC). Eleven serum miRNAs 
were  found  to  be  altered  more  than  five-fold  by  Solexa  sequencing  between  longer-survival  and 
shorter-survival groups, and levels of four miRNAs (i.e., miR-486, miR-30d, miR-1 and miR-499) 
were significantly associated with overall survival. Int. J. Mol. Sci. 2011, 12                       
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Table 1. Circulating miRNAs as biomarkers of tumor. 
Tumor Type  MicroRNAs  Significance  References 
Breast cancer  miR-195 and let-7a; 
miRNA-21, 106a, 126, 
155, 199a and 335 
Correlated with nodal status 
and estrogen receptor status, 
and decreased postoperatively 
[27,33] 
CRC  miR-92; miR-29a and 
miR-92a 
Diagnosis with 70% 
specificity and 89% 
sensitivity; early detection of 
CRC 
[34,35] 
DLBCL  miR-21  Relapse-free survival  [30] 
Gastric cancer  miR-17-5p, miR-21,  
miR-106a, miR-106b,  
let-7a; miR-1, miR-20a, 
miR-27a, miR-34 and  
miR-423-5p 
Up or down-regulated; 
Correlated to tumor stage 
[26,36] 
HCC  miR-92a; miR-500;  
miR-25, miR-375, and  
let-7f 
Down-regulated, up-regulated 
after surgical treatment, and 
diagnosis 
[28,37,38] 
Leukemia  miR-92a/miR-638;  
miR-29a, -181a, and -221 
Diagnosis and treatment  [39,40] 
Melanoma  gene profiles  21 miRNAs down-regulated 
/30 miRNAs up-regulated 
[31] 
MM  miR-193b-365  Up-regulated  [41] 
NSCLC  miR-25 and miR-223; 
exosomal miRNA;  
miR-486, miR-30d, miR-1 
and miR-499 
Up-regulated; screening test; 
overall survival 
[19,24,32] 
Oral cancer   miR-31; miR-184  Up-regulated, and  
down-regulated after surgical 
resection.; diagnosis 
[21,42] 
Ovarian cancer  miRNAs-21, 92, 93, 126 
and 29a; MiRNAs-155, 
127 and 99b 
Up-regulated, and related 
with pre-operative CA-125;  
down-regulated; exosomes 
[43–45] 
Pancreatic cancer  miR-21, miR-210,  
miR-155, and miR-196a 
Diagnosis  [25,46–48] 
Prostate cancer  miR-141  Diagnosis  [18] 
ESCC  miR-10a, miR-22,  
miR-100, miR-148b,  
miR-223, miR-133a, and 
miR-127-3p 
Up-regulated  [49] 
Rhabdomyosarcoma  miR-206  Up-regulated  [50] 
CRC: colorectal carcinoma; DLBCL: diffuse large B cell lymphoma; HCC: hepatocellular carcinoma; 
MM: Multiple myeloma; ESCC: esophageal squamous cell carcinoma.  Int. J. Mol. Sci. 2011, 12                       
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7. Perspectives 
Together,  these  results  indicate  that  circulating  miRNAs  have  many  characteristics  of  ideal 
biomarkers,  most  notably  their  inherent  stability  and  resilience.  Firstly,  miRNA  expression  is 
frequently dysregulated in cancer [3,6]. Secondly, expression patterns of miRNAs in human cancer 
appear to be tissue-specific [15]. Thirdly, miRNAs have unusually high stability [4]. The expression 
of specific  circulating  miRNAs  is  a  good  surrogate  of  tumor  miRNA  expression  and  initiates  a 
new paradigm  that  will  be  useful  not  only  for  early  diagnosis  but  also  for  prognostic  and  
therapeutic decisions [51].  
Furthermore,  a  lot of challenges  regarding miRNAs  in  sera need  to be  confronted. Firstly, the 
specificity of miRNAs: one miRNA can distinguish different cancers which have the same serum 
miRNA, e.g., miR-21 in DLBCL and pancreatic cancer. Secondly, the standardization of miRNAs: the 
preparation of serum/plasma will need be standardized in order to generalize findings from different 
patients, groups, or labs. Thirdly, the quantification of miRNAs: what will be used as a standard for 
qRT-PCR for measuring circulating miRNAs (e.g., as ―housekeeping‖ serum miRNA/small RNA), as 
other classes of RNAs or mRNAs are not stable in serum? Apart from these issues, questions about the 
biological half-life of the circulating miRs need to be addressed, as this has critical effects in clinical 
applications. Therefore, the functional roles of miRNAs in tumor biology are currently being unraveled 
and worth further investigations. 
References 
1.  Etzioni, R.; Urban, N.; Ramsey, S.; McIntosh, M.; Schwartz, S.; Reid, B.; Radich, J.; Anderson, G.; 
Hartwell, L. The case for early detection. Nat. Rev. Cancer 2003, 3, 243–252. 
2.  Schetter, A.J.; Harris, C.C. Plasma microRNAs: a potential biomarker for colorectal cancer? Gut 
2009, 58, 1318–1319. 
3.  Calin, G.A.; Croce C.M. MicroRNA signatures in human cancers. Nat. Rev. Cancer 2006, 6,  
857–866. 
4.  Cho,  W.C.  Molecular  diagnostics  for  monitoring  and  predicting  therapeutic  effect  in  cancer. 
Expert Rev. Mol. Diagn. 2011, 11, 9–12. 
5.  Griffiths-Jones, S.; Saini, H.K.; van Dongen, S.; Enright, A.J. miRBase: Tools for microRNA 
genomics. Nucleic Acids Res. 2008, 36, D154–D158. 
6.  Esquela-Kerscher, A.; Slack, F.J. Oncomirs—microRNAs with a role in cancer. Nat. Rev. Cancer 
2006, 6, 259–269. 
7.  Calin, G.A.; Sevignani, C.; Dumitru, C.D.; Hyslop, T.; Noch, E.; Yendamuri, S.; Shimizu, M.; 
Rattan, S.; Bullrich, F.; Negrini, M.; Croce, C.M. Human microRNA genes are frequently located 
at fragile sites and genomic regions involved in cancers. Proc. Natl. Acad. Sci. USA 2004, 101, 
2999–3004. 
8.  Garzon, R.; Calin, G.A.; Croce, C.M. MicroRNAs in Cancer. Annu. Rev. Med. 2009, 60, 167–179. 
9.  Landi,  M.T.;  Zhao,  Y.;  Rotunno,  M.;  Koshiol,  J.;  Liu,  H.;  Bergen,  A.W.;  Rubagotti,  M.; 
Goldstein,  A.M.;  Linnoila,  I.;  Marincola,  F.M.;  et  al.  MicroRNA  expression  differentiates 
histology and predicts survival of lung cancer. Clin. Cancer Res. 2010, 16, 430–441. Int. J. Mol. Sci. 2011, 12                       
 
 
2061 
10.  Cimmino, A.; Calin, G.A.; Fabbri, M.; Iorio, M.V.; Ferracin, M.; Shimizu, M.; Wojcik, S,E.; 
Aqeilan, R.I.; Zupo, S.; Dono, M.; et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. 
Proc. Natl. Acad. Sci. USA 2005, 102, 13944–13949. 
11.  Guo, J.; Miao, Y.; Xiao, B.; Huan, R.; Jiang, Z.; Meng, D.; Wang, Y. Differential expression of 
microRNA  species  in  human  gastric  cancer  versus  non-tumorous  tissues.  J  Gastroenterol. 
Hepatol. 2009, 24, 652–657. 
12.  Asaga, S.; Kuo, C.; Nguyen, T.; Terpenning, M.; Giuliano, A.E.; Hoon, D.S. Direct serum assay 
for microRNA-21 concentrations in early and advanced breast cancer. Clin. Chem. 2011, 57, 84–91. 
13.  Cho, W.C. MicroRNAs in cancer–from research to therapy. Biochim. Biophys. Acta 2010, 1805, 
209–217. 
14.  Cho,  W.C.  MicroRNAs:  Potential  biomarkers  for  cancer  diagnosis,  prognosis  and  targets  for 
therapy. Int. J. Biochem. Cell Biol. 2010, 42, 1273–1281. 
15.  Lu, J.;  Getz, G.;  Miska, E.A.;  Alvarez-Saavedra, E.;  Lamb, J.; Peck, D.; Sweet-Cordero, A.; 
Ebert, B.L.; Mak, R.H.; Ferrando, A.A.; et al. MicroRNA expression profiles classify human 
cancers. Nature 2005, 435, 834–838. 
16.  Segura,  M.F.;  Belitskaya-Lé vy,  I.;  Rose,  A.E.;  Zakrzewski,  J.;  Gaziel,  A.;  Hanniford,  D.; 
Darvishian, F.; Berman, R.S.; Shapiro, R.L.; Pavlick, A.C.; et al. Melanoma MicroRNA signature 
predicts post-recurrence survival. Clin. Cancer Res. 2010, 16, 1577–1586. 
17.  Yu, S.L.; Chen, H.Y.; Chang, G.C.; Chen, C.Y.; Chen, H.W.; Singh, S.; Cheng, C.L.; Yu, C.J.; 
Lee, Y.C.; Chen, H.S.; et al. MicroRNA signature predicts survival and relapse in lung cancer. 
Cancer Cell 2008, 13, 48–57. 
18.  Mitchell, P.S.; Parkin, R.K.; Kroh, E.M.; Fritz, B.R.; Wyman, S.K.; Pogosova-Agadjanyan, E.L.; 
Peterson, A.; Noteboom, J.; O'Briant, K.C.; Allen, A.; et al. Circulating microRNAs as stable 
blood-based markers for cancer detection. Proc. Natl. Acad. Sci. USA 2008, 105, 10513–10518. 
19.  Chen, X.; Ba, Y.; Ma, L.; Cai, X.; Yin, Y.; Wang, K.; Guo, J.; Zhang, Y.; Chen, J.; Guo, X.; et al. 
Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and 
other diseases. Cell Res. 2008, 18, 997–1006. 
20.  Li, J.; Smyth, P.; Flavin, R.; Cahill, S.; Denning, K.; Aherne, S.; Guenther, S.M.; O'Leary, J.J.; 
Sheils, O. Comparison of miRNA expression patterns using total RNA extracted from matched 
samples  of  formalin-fixed  paraffin–embedded  (FFPE)  cells  and  snap-frozen  cells.  BMC 
Biotechnol. 2007, 7, 36. 
21.  Wong,  T.S.;  Liu,  X.B.;  Wong,  B.Y.;  Ng,  R.W.;  Yuen,  A.P.;  Wei,  W.I.  Mature  miR-184  as 
potential oncogenic microRNA of squamous cell carcinoma of tongue. Clin. Cancer Res 2008, 14, 
2588–2592. 
22.  Valadi, H.; Ekströ m, K.; Bossios, A.; Sjö strand, M.; Lee, J.J.; Lö tvall, J.O. Exosome-mediated 
transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells.  
Nat. Cell Biol. 2007, 9, 654–659. 
23.  Kosaka,  N.;  Iguchi,  H.;  Yoshioka,  Y.;  Takeshita,  F.;  Matsuki,  Y.;  Ochiya,  T.;  Secretory 
mechanisms and intercellular transfer of microRNAs in living cells. J. Biol. Chem. 2010, 285, 
17442–17452. 
24.  Rabinowits,  G.;  Gerç el-Taylor,  C.;  Day,  J.M.;  Taylor,  D.D.;  Kloecker,  G.H.  Exosomal 
microRNA: A diagnostic marker for lung cancer. Clin. Lung Cancer 2009, 10, 42–46. Int. J. Mol. Sci. 2011, 12                       
 
 
2062 
25.  Li, A.; Omura, N.; Hong, S.M.; Vincent, A.; Walter, K.; Griffith, M.; Borges, M.; Goggins, M. 
Pancreatic  cancers  epigenetically  silence  SIP1  and  hypomethylate  and  overexpress  
miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels. Cancer 
Res. 2010, 70, 5226–5237. 
26.  Tsujiura, M.; Ichikawa, D.; Komatsu, S.; Shiozaki, A.; Takeshita, H.; Kosuga, T.; Konishi, H.; 
Morimura, R.; Deguchi, K.; Fujiwara, H.; Okamoto, K.; Otsuji, E. Circulating microRNAs in 
plasma of patients with gastric cancers. Br. J. Cancer. 2010, 102, 1174–1179. 
27.  Heneghan, H.M.; Miller, N.; Lowery, A.J.; Sweeney, K.J.; Newell, J.; Kerin, M.J. Circulating 
microRNAs as novel minimally invasive biomarkers for breast cancer.  Ann. Surg. 2010, 251, 
499–505. 
28.  Shigoka,  M.;  Tsuchida,  A.;  Matsudo,  T.;  Nagakawa,  Y.;  Saito,  H.;  Suzuki,  Y.;  Aoki,  T.; 
Murakami, Y.; Toyoda, H.; Kumada, T. Deregulation of miR-92a expression is implicated in 
hepatocellular carcinoma development. Pathol. Int. 2010, 60, 351–357. 
29.  Calin,  G.A.;  Liu,  C.G.;  Sevignani,  C.;  Ferracin,  M.;  Felli,  N.;  Dumitru,  C.D.;  Shimizu,  M.; 
Cimmino,  A.;  Zupo,  S.;  Dono,  M.  MicroRNA  profiling  reveals  distinct  signatures  in  B  cell 
chronic lymphocytic leukemias. Proc. Natl. Acad. Sci. USA 2004, 101, 11755–11760. 
30.  Lawrie, C.H.; Gal, S.; Dunlop, H.M.; Pushkaran, B.; Liggins, A.P.; Pulford, K.; Banham, A.H.; 
Pezzella, F.; Boultwood, J.;  Wainscoat, J.S.; Hatton, C.S.; Harris, A.L. Detection of elevated 
levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. 
Br. J. Haematol. 2008, 141, 672–675. 
31.  Leidinger, P.; Keller, A.; Borries, A.; Reichrath, J.; Rass, K.; Jager, S.U.; Lenhof, H.P.; Meese, E. 
High-throughput miRNA profiling of human melanoma blood samples. BMC Cancer 2010, 10, 262. 
32.  Hu, Z.; Chen, X.; Zhao, Y.; Tian, T.; Jin, G.; Shu, Y.; Chen, Y.; Xu, L.; Zen, K.; Zhang, C.; et al. 
Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling 
predict survival of non-small-cell lung cancer. J. Clin. Oncol. 2010, 28, 1721–1726. 
33.  Wang,  F.;  Zheng,  Z.;  Guo,  J.;  Ding,  X.  Correlation  and  quantitation  of  microRNA  aberrant 
expression in tissues and sera from patients with breast tumor. Gynecol Oncol. 2010, 119, 586–593. 
34.  Ng, E.K.; Chong, W.W.; Jin, H.; Lam, E.K.; Shin, V.Y.; Yu, J.; Poon, T.C.; Ng, S.S.; Sung, J.J. 
Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential 
marker for colorectal cancer screening. Gut 2009, 58, 1375–1381. 
35.  Huang, Z.; Huang, D.; Ni, S.; Peng, Z.; Sheng, W.; Du, X. Plasma microRNAs are promising 
novel biomarkers for early detection of colorectal cancer. Int. J. Cancer 2010, 127, 118–126. 
36.  Liu,  R.;  Zhang,  C.;  Hu,  Z.;  Li,  G.;  Wang,  C.;  Yang,  C.;  Huang,  D.;  Chen,  X.;  Zhang,  H.; 
Zhuang, R.; et al. A five-microRNA signature identified from genome-wide serum microRNA 
expression profiling serves as a fingerprint for gastric cancer diagnosis. Eur. J. Cancer 2010, 9, 26. 
37.  Yamamoto, Y.; Kosaka, N.; Tanaka, M.; Koizumi, F.; Kanai, Y.; Mizutani, T.; Murakami, Y.; 
Kuroda, M.; Miyajima, A.; Kato, T.; et al. MicroRNA-500 as a potential diagnostic marker for 
hepatocellular carcinoma. Biomarkers 2009, 14, 529–538. 
38.  Li, L.M.; Hu, Z.B.; Zhou, Z.X.; Chen, X.; Liu, F.Y.; Zhang, J.F.; Shen, H.B.; Zhang, C.Y.; Zen, K. 
Serum  microRNA  profiles  serve  as  novel  biomarkers  for  HBV  infection  and  diagnosis  of  
HBV-positive hepatocarcinoma. Cancer Res. 2010, 70, 9798–9807. Int. J. Mol. Sci. 2011, 12                       
 
 
2063 
39.  Tanaka, M.; Oikawa, K.; Takanashi, M.; Kudo, M.; Ohyashiki, J.; Ohyashiki, K.; Kuroda, M. 
Down-regulation  of  miR-92  in  human  plasma  is  a  novel  marker  for  acute  leukemia  patients.  
PLoS One 2009, 4, e5532. 
40.  Moussay,  E.;  Palissot,  V.;  Vallar,  L.;  Poirel,  H.A.;  Wenner,  T.;  El  Khoury,  V.;  Aouali,  N.; 
van Moer, K.; Leners, B.; Bernardin, F.; et al. Determination of genes and microRNAs involved in 
the resistance to fludarabine in vivo in chronic lymphocytic leukemia. Mol. Cancer 2010, 20, 115. 
41.  Unno, K.; Zhou, Y.; Zimmerman, T.; Platanias, L.C.; Wickrema, A. Identification of a novel 
microRNA cluster miR-193b-365 in multiple myeloma. Leuk. Lymphoma 2009, 50, 1865–1871. 
42.  Liu,  C.J.;  Kao,  S.Y.;  Tu,  H.F.;  Tsai,  M.M.;  Chang,  K.W.;  Lin,  S.C.  Increase  of  microRNA  
miR-31 level in plasma could be a potential marker of oral cancer. Oral Dis. 2010, 16, 360–364. 
43.  Resnick, K.E.; Alder, H.; Hagan, J.P.; Richardson, D.L.; Croce, C.M.; Cohn, D.E. The detection 
of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel 
real–time PCR platform. Gynecol. Oncol. 2009, 112, 55–59. 
44.  Hä usler, S.F.; Keller, A.; Chandran, P.A.; Ziegler, K.; Zipp, K.; Heuer, S.; Krockenberger, M.; 
Engel, J.B.; Hö nig, A.; Scheffler, M.; et al. Whole blood-derived miRNA profiles as potential 
new tools for ovarian cancer screening. Br. J. Cancer 2010, 103, 693–700. 
45.  Taylor, D.D.; Gercel-Taylor, C. MicroRNA signatures of tumor-derived exosomes as diagnostic 
biomarkers of ovarian cancer. Gynecol. Oncol. 2008, 110, 13–21. 
46.  Wang, J.; Chen, J.; Chang, P.; LeBlanc, A.; Li, D.; Abbruzzesse, J.L.; Frazier, M.L.; Killary, A.M.; 
Sen, S. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based 
biomarkers of disease. Cancer Prev. Res. (Phila Pa) 2009, 2, 807–813. 
47.  Ho, A.S.; Huang, X.; Cao, H.; Christman-Skieller, C.; Bennewith, K.; Le, Q.T.; Koong, A.C. 
Circulating, miR-210 as a novel hypoxia marker in pancreatic cancer. Transl. Oncol. 2010, 3,  
109–113. 
48.  Ali, S.; Almhanna, K.; Chen, W.; Philip, P.A.; Sarkar, F.H. Differentially expressed miRNAs in 
the plasma may provide a molecular signature for aggressive pancreatic cancer. Am. J. Transl. 
Res. 2010, 3, 28–47. 
49.  Zhang,  C.;  Wang,  C.;  Chen,  X.;  Yang,  C.;  Li,  K.;  Wang,  J.;  Dai,  J.;  Hu,  Z.;  Zhou,  X.;  
Chen, L.; et al. Expression profile of microRNAs in serum: a fingerprint for esophageal squamous 
cell carcinoma. Clin. Chem. 2010, 56, 1871–1879. 
50.  Miyachi,  M.;  Tsuchiya,  K.;  Yoshida,  H.;  Yagyu,  S.;  Kikuchi,  K.;  Misawa,  A.;  Iehara,  T.;  
Hosoi, H. Circulating muscle-specific microRNA, miR-206, as a potential diagnostic marker for 
rhabdomyosarcoma. Biochem. Biophys. Res. Commun. 2010, 400, 89–93.  
51.  Brase, J.C.; Wuttig, D.; Kuner, R.; Sü ltmann, H. Serum microRNAs as non-invasive biomarkers 
for cancer. Mol. Cancer 2010, 26, 306. 
©  2011  by  the authors;  licensee  MDPI,  Basel,  Switzerland.  This  article  is  an  open  access  article 
distributed  under  the  terms  and  conditions  of  the  Creative  Commons  Attribution  license 
(http://creativecommons.org/licenses/by/3.0/). 